Hecht, Markus https://orcid.org/0000-0003-2082-216X
Gostian, Antoniu Oreste
Eckstein, Markus https://orcid.org/0000-0001-5418-3349
Rutzner, Sandra
von der Grün, Jens
Illmer, Thomas
Hautmann, Matthias G
Klautke, Gunther
Laban, Simon
Brunner, Thomas
Hinke, Axel
Becker, Ina
Frey, Benjamin https://orcid.org/0000-0001-6743-3351
Semrau, Sabine
Geppert, Carol I
Hartmann, Arndt
Balermpas, Panagiotis
Budach, Wilfried
Gaipl, Udo S
Iro, Heinrich
Fietkau, Rainer
Clinical trials referenced in this document:
Documents that mention this clinical trial
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer
https://doi.org/10.1136/jitc-2021-003747
F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial
https://doi.org/10.1007/s12149-022-01744-6
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
https://doi.org/10.1136/jitc-2020-001378
Documents that mention this clinical trial
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer
https://doi.org/10.1136/jitc-2021-003747
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
https://doi.org/10.1136/jitc-2020-001378
Funding for this research was provided by:
AstraZeneca (ESR-16-12356)